Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31571148 | 1.00 | ALOX15 (0.46) | ALOX15MAPTKDM4EBRD4CA12 | |
| SCHEMBL2724703 | 0.89 | BRD4 (0.50) | MAPTKDM4EBRD4ACVR1NCF1 | |
| SCHEMBL26259967 | 0.87 | BRD4 (0.53) | MAPTKDM4EBRD4NPC1TP53 | |
| SCHEMBL11363800 | 0.79 | BRD4 (0.57) | MAPTKDM4EBRD4NCF1NPC1 | |
| SCHEMBL198641 | 0.79 | MAPT (0.64) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL50810 | 0.79 | ALDH1A1 (0.51) | ALOX15MAPTKDM4EBRD4NCF1 | |
| SCHEMBL7918743 | 0.77 | MAPT (0.56) | MAPTKDM4ECA12CA1CA2 | |
| SCHEMBL29005597 | 0.77 | KDM4E (0.58) | ALOX15MAPTKDM4ECA12CA1 | |
| SCHEMBL29364102 | 0.77 | KDM4E (0.58) | ALOX15MAPTKDM4ECA12CA1 | |
| SCHEMBL11444284 | 0.77 | PLAU (0.46) | KDM4EBRD4POLBNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | claimed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | claimed |
| EP-4472734-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X Discovery Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023148501-A1 | HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS | C4X DISCOVERY LIMITED (GB) | 2023-08-10 | — | — | WO | disclosed |
| CN-105498052-A | Apparatus and method for aerosol delivery to the lungs or other locations of the body | PENN-CENTURY INC | 2016-04-20 | — | — | CN | disclosed |
| CN-102883765-B | Device and method for delivering aerosol to the lungs or other locations of the body | Penn-Century, Inc. (US) | 2015-12-09 | — | — | CN | disclosed |
| US-8974771-B2 | Apparatus and method for aerosol delivery to the lungs or other locations of the body | Penn-Century, Inc. (US) | 2015-03-10 | — | — | US | disclosed |
| CN-101547920-B | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORP | 2012-06-27 | — | — | CN | disclosed |
| US-20110223116-A1 | APPARATUS AND METHOD FOR AEROSOL DELIVERY TO THE LUNGS OR OTHER LOCATIONS OF THE BODY | Penn-Century, Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100324295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| CN-101796049-A | Process for preparing substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| CN-101796049-A | Process for preparing substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| EP-2178867-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| CN-101547920-A | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORP (US) | 2009-09-30 | — | — | CN | disclosed |
| WO-2009009003-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | ALOX15 3568/4885MAPT 1830/4885KDM4E 4332/4885 |
| US-20100324295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PDE4B, PDE4A, PDE3B | ALOX15 3166/4885MAPT 4571/4885KDM4E 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.